- Home
- AQST
as 06-20-2025 4:00pm EST
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | WARREN |
| Market Cap: | 272.9M | IPO Year: | 2018 |
| Target Price: | $10.67 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.12 - $5.80 | Next Earning Date: | 08-05-2025 |
| Revenue: | $54,228,000 | Revenue Growth: | 5.29% |
| Revenue Growth (this year): | -20.15% | Revenue Growth (next year): | 45.71% |
Latest Aquestive Therapeutics Inc. News
AQST Breaking Stock News: Dive into AQST Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Aquestive Gets FDA Acceptance of New Drug Application for Severe Allergic Reaction Treatment
GlobeNewswire
5 days ago
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions
Simply Wall St.
a month ago
Those who invested in Aquestive Therapeutics (NASDAQ:AQST) three years ago are up 128%
Insider Monkey
a month ago
Aquestive Therapeutics, Inc. (AQST): Analysts See 245% Upside Potential
GuruFocus.com
a month ago
Aquestive Therapeutics Inc (AQST) Q1 2025 Earnings Call Highlights: Navigating Revenue Declines ...
Zacks
a month ago
Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks
a month ago
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates
Associated Press Finance
a month ago
Aquestive Therapeutics: Q1 Earnings Snapshot
Compare AQST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AQST Aquestive Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.